Domainex and ICL team up to discover myocardial infarction therapies
Posted: 20 October 2015 | Victoria White
Domainex has been selected as Imperial’s strategic drug discovery partner to provide services including biochemical and biophysical assay development…
The announcement follows the success of Imperial in securing £3 million in funding from the Wellcome Trust Seeding Drug Discovery programme to build upon the pioneering research of Professor Michael Schneider, the British Heart Foundation Simon Marks Chair in Regenerative Cardiology.
One of the key research activities of Professor Schneider’s group in Imperial’s National Heart and Lung Institute is to identify the enzyme pathways activated by cardiac stress that result in the apoptosis of cardiac muscle cells. The potential for using these findings to prevent cardiac muscle cell death following a heart attack has resulted in this research award from the Wellcome Trust. Domainex has been chosen as Imperial’s strategic drug discovery partner to provide services including biochemical and biophysical assay development, compound screening and medicinal chemistry to advance the project towards pre-clinical development.
Domainex to deliver candidate drug molecules
Professor Schneider said, “Our target is activated, invariably, in diseased human hearts, and its suppression already protects human heart muscle cells from dying in the laboratory. If we can succeed in taking this forward as a new therapy for myocardial infarction, this would have major benefits for patients, their families, and healthcare providers alike.
“Based upon Domainex’s knowledge and approach to drug discovery, we anticipate a fruitful collaboration with them”.
Domainex will undertake integrated lead identification and optimisation studies on the serine/threonine protein kinase enzyme target mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). In this collaboration Domainex will seek to deliver candidate drug molecules meeting a series of defined criteria.